Search results for " low-density lipoprotein size"

showing 2 items of 2 documents

Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea.

2012

Patients with obstructive sleep apnea (OSA) have proatherogenic dyslipidemia. We analyzed predictors of low-density lipoproteins' (LDLs) size in patients with OSA. In a cross-sectional study including 58 participants with OSA (30 without the metabolic syndrome [MetS] and 28 with MetS), we evaluated the size of LDL by gradient gel electrophoresis. Compared with patients without the MetS, those with MetS showed lower LDL size ( P = .007), due to a reduction in large LDL-I particles ( P = .002) and an increase in small, dense LDL-IIIA ( P = .048) and LDL-IIIB ( P = .037). The size of LDL correlated inversely with age ( r = −.268, P = .042) and serum triglycerides ( r = −.364, P = .005), and p…

medicine.medical_specialtyCross-sectional studyPolysomnography10265 Clinic for Endocrinology and Diabetology610 Medicine & healthPolysomnography2705 Cardiology and Cardiovascular MedicineInternal medicinemedicineLow densityobstructive sleep apnea metabolic syndrome low-density lipoprotein size small dense low-density lipoprotein atherosclerosisHumansIn patientDyslipidemiasMetabolic SyndromeSleep Apnea Obstructivemedicine.diagnostic_testbusiness.industrySleep apneamedicine.diseaseLipoproteins LDLObstructive sleep apneaCross-Sectional StudiesEndocrinologyLinear Modelslipids (amino acids peptides and proteins)Metabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemia
researchProduct

The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

2008

Diabetic dyslipidemia is typically characterized by an increase in plasma triglycerides, a decrease in high-density lipoprotein cholesterol and a concomitant increase in atherogenic small dense low-density lipoproteins. Thiazolidindiones are able to lower the levels of fasting glucose and glycated hemoglobin significantly by improving insulin sensitivity, as well as improving some aspects of diabetic dyslipidemia: total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol tend to increase while triglycerides are generally decreased.This paper reviewed the effects of pioglitazone and rosiglitazone on atherogenic diabetic dyslipidemia, in particular on sma…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthType 2 diabetesRosiglitazonechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicine2736 Pharmacology (medical)HumansHypoglycemic AgentsPharmacology (medical)Clinical significancecardiovascular risk dense low-density lipoprotein diabetes low-density lipoprotein size pioglitazone rosiglitazone smallTriglyceridesDyslipidemiasPharmacologyAtherogenic dyslipidemiaPioglitazonebusiness.industryThiazolidindionesAtherogenic dyslipidemiaGeneral Medicinemedicine.diseaseLipoproteins LDLEndocrinology3004 PharmacologychemistryDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)ThiazolidinedionesGlycated hemoglobinbusinessRosiglitazoneLipoproteins HDLPioglitazoneBiomarkersmedicine.drugLipoprotein
researchProduct